Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

bausch health ireland limited, dublin array - 885 megestrol-acetÁt - perorální suspenze - 40mg/ml - megestrol

Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmaswiss Česká republika s.r.o. - megestrolacetat - peroralna suspenzija - megestrolacetat 40 mg / 1 ml - megestrol

Serbia - serbisk - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

pharmaswiss d.o.o., beograd - мегестрола - oralna suspenzija - 40mg/ml

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace® es oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). enter section text here therapy with megestrol acetate for weight loss should only be instituted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megestrol acetate is not intended for prophylactic use to avoid weight loss. enter section text here history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy. enter section text here pregnancy category x [ see warnings and precautions: (5.2)]. no adequate animal teratology information is available at clinically relevant doses. pregnant rats treated with low doses of megestrol acetate (0.02-fold the recommen

USA - engelsk - NLM (National Library of Medicine)

endo pharmaceuticals inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace es is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). limitations of use therapy with megace es for weight loss should only be insti­tuted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megace es is not intended for prophylactic use to avoid weight loss. - history of hypersensitivity to megestrol acetate or any component of the formulation. - pregnancy [see warnings and precautions (5.2), use in specific populations (8.1, 8.3)]. risk summary based on animal data, megestrol acetate may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy [see contraindications (4)] . there are no available human data to assess for any drug-associated risks of miscar

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pharmaswiss ceska republika s.r.o. - megestrol acetate - oral suspension - 40 milligram(s)/millilitre - progestogens; megestrol

Irland - engelsk - HPRA (Health Products Regulatory Authority)

bausch health ireland limited - megestrol acetate - oral suspension - 40 milligram(s)/millilitre - progestogens; megestrol

Canada - fransk - Health Canada

bristol-myers squibb canada - acétate de mégestrol - suspension - 40mg - acétate de mégestrol 40mg - antineoplastic agents

USA - engelsk - NLM (National Library of Medicine)

stat rx usa - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace ® es (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy.

USA - engelsk - NLM (National Library of Medicine)

atlantic biologicals corps - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - other treatable causes prophylactic use megestrol acetate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. megestrol acetate has had limited use in hiv infected women. all 10 women in the clinical trials reported breakthrough bleeding. megace es is a progesterone derivative, which may induce vaginal bleeding in women. ®